Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-cash Items (2016 - 2022)

Historic Non-cash Items for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Q1 2022 value amounting to $2.3 million.

  • Arrowhead Pharmaceuticals' Non-cash Items fell 347.91% to $2.3 million in Q1 2022 from the same period last year, while for Mar 2022 it was $2.3 million, marking a year-over-year decrease of 347.91%. This contributed to the annual value of $149.5 million for FY2021, which is 1580.23% up from last year.
  • Arrowhead Pharmaceuticals' Non-cash Items amounted to $2.3 million in Q1 2022, which was down 347.91% from $2.5 million recorded in Q4 2021.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Non-cash Items peaked at $149.5 million during Q3 2021, and registered a low of $2.3 million during Q1 2022.
  • For the 5-year period, Arrowhead Pharmaceuticals' Non-cash Items averaged around $36.3 million, with its median value being $3.7 million (2018).
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 1104852.03% in 2018, then tumbled by 9819.09% in 2021.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Non-cash Items stood at $3.7 million in 2018, then dropped by 13.58% to $3.2 million in 2019, then decreased by 19.77% to $2.6 million in 2020, then dropped by 3.75% to $2.5 million in 2021, then fell by 4.79% to $2.3 million in 2022.
  • Its Non-cash Items stands at $2.3 million for Q1 2022, versus $2.5 million for Q4 2021 and $149.5 million for Q3 2021.